首页> 外文期刊>Brachytherapy >High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.
【24h】

High-dose-rate brachytherapy for localized prostate adenocarcinoma post abdominoperineal resection of the rectum and pelvic irradiation: Technique and experience.

机译:大剂量率近距离放射疗法对直肠腹部切除术后盆腔放疗后局限性前列腺腺癌的治疗:技术和经验。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Treatment options are limited for patients with localized prostate cancer and a prior history of abdominoperineal resection (APR) and pelvic irradiation. We have previously reported on the successful utility of high-dose-rate (HDR) brachytherapy salvage for prostate cancer failing definitive external beam radiation therapy (EBRT). In this report, we describe our technique and early experience with definitive HDR brachytherapy in patients post APR and pelvic EBRT. PATIENTS AND METHODS: Six men with newly diagnosed localized prostate cancer had a prior history of APR and pelvic EBRT. Sixteen to 18 HDR catheters were placed transperineally under transperineal ultrasound-guidance. The critical first two catheters were placed freehand posterior to the inferior rami on both sides of the bulbar urethra under cystoscopic visualization. A template was used for subsequent catheter placement. Using CT-based planning, 5 men received 36Gy in six fractions as monotherapy. One patient initially treated with EBRT to 30Gy, received 24Gy in four fractions. RESULTS: Median age was 67.5 (56-74) years. At a median followup of 26 (14-60) months, all patients are alive and with no evidence of disease per the Phoenix definition of biochemical failure, with a median prostate-specific antigen nadir of 0.19ng/mL. Three men have reported grade 2 late genitourinary toxicity. There has been no report of grade 3-5 toxicity. CONCLUSION: Transperineal ultrasound-guided HDR brachytherapy using the above technique should be considered as definitive therapy for patients with localized prostate cancer and a prior history of APR and pelvic EBRT.
机译:目的:对于局限性前列腺癌,腹部手术切除(APR)和骨盆照射的既往病史的患者,治疗选择是有限的。先前我们已经报道了高剂量率(HDR)近距离疗法挽救成功用于确定性外束放射疗法(EBRT)失败的前列腺癌的成功应用。在本报告中,我们描述了APR和骨盆EBRT后患者进行明确的HDR近距离治疗的技术和早期经验。患者和方法:六名新诊断为局限性前列腺癌的男性曾有APR和骨盆EBRT病史。经会阴超声引导经会阴放置16至18个HDR导管。在膀胱镜检查下,将关键的前两个导管徒手放在下尿道的后方,位于球状尿道的两侧。模板用于随后的导管放置。使用基于CT的计划,有5名男性接受了6次36Gy的单药治疗。一名最初接受EBRT至30Gy的患者,分四次接受24Gy。结果:中位年龄为67.5(56-74)岁。在中位随访26(14-60)个月时,所有患者均活着,并且根据Phoenix对生化衰竭的定义没有任何疾病的证据,中位前列腺特异性抗原最低值为0.19ng / mL。三名男子报告了2级晚期泌尿生殖系统毒性。没有关于3-5级毒性的报道。结论:采用上述技术的经会阴超声引导的HDR近距离放射治疗应被认为是局部前列腺癌,APR和骨盆EBRT既往病史的明确治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号